Results 261 to 270 of about 7,530,679 (394)
Pancreatic ductal adenocarcinoma (PDAC) is a disease with very poor prognosis due to therapeutic limitations. We investigated the antitumor effects of cystatin A (CSTA) in PDAC murine models. We are first to confirm that CSTA enhances T helper type 1‐mediated antitumor effects through promotion of dendritic cells and M1 macrophage activity. CSTA can be
Alessandro Nasti+8 more
wiley +1 more source
A Critical Review of Recent Advances in Maize Stress Molecular Biology. [PDF]
Meng L, Zhang J, Clarke N.
europepmc +1 more source
"Molecular Biology"-Pleonasm or Denotation for a Discipline of Its Own? Reflections on the Origins of Molecular Biology and Its Situation Today. [PDF]
Greslehner GP.
europepmc +1 more source
Cell‐free DNA aneuploidy score as a dynamic early response marker in prostate cancer
mFast‐SeqS‐based genome‐wide aneuploidy scores are concordant with aneuploidy scores obtained by whole genome sequencing from tumor tissue and can predict response to ARSI treatment at baseline and, at an early time point, to ARSI and taxanes. This assay can be easily performed at low cost and requires little input of cfDNA. Cell‐free circulating tumor
Khrystany T. Isebia+17 more
wiley +1 more source
Companion Diagnostics (CDx) Based on Molecular Biology Techniques. [PDF]
Kang SL, Kwon JY, Kim SM.
europepmc +1 more source
Virology: Molecular biology of the coronaviruses [PDF]
Brian W. J. Mahy
openalex +1 more source
Prostate cancer is a leading malignancy with significant clinical heterogeneity in men. An 11‐gene signature derived from dysregulated epithelial cell markers effectively predicted biochemical recurrence‐free survival in patients who underwent radical surgery or radiotherapy.
Zhuofan Mou, Lorna W. Harries
wiley +1 more source
Clinical significance of stratifying prostate cancer patients through specific circulating genes
We tested a specific panel of genes representative of luminal, neuroendocrine and stem‐like cells in the blood of prostate cancer patients, showing predictive value from diagnosis to late stages of disease. This approach allows monitoring of treatment responses and outcomes at specific time points in trajectories.
Seta Derderian+12 more
wiley +1 more source